June 13, 2012
Paul E. Sax, M.D., is director of the HIV Program and Division of Infectious Diseases at Brigham and Women's Hospital in Boston.
The single case of HIV cure following allogeneic bone marrow transplant is in the news again, this time because of data just presented at "The International Workshop on HIV and Hepatitis Virus Drug Resistance and Curative Strategies" (formerly known as the "HIV Resistance Workshop" -- how's that for rebranding?).
I'm not at the meeting, which is too bad since they often have it in splendid locations.
But from what I gather based on the report, here are the key findings in the study:
My gut feeling is that the findings are potentially real, but unlikely to be of much clinical significance if virus can only be detected intermittently by special assays, especially since he's been off all HIV treatment for more than 5 years.
But they may not be real -- we need to remember that a false positive test result is more likely when the test's sensitivity is cranked up and it's performed multiple times.
Or as more colorfully put by Doug Richman:
If you do enough cycles of PCR, you can get a signal in water for pink elephants.
And if this interesting presentation tells us anything, it's that defining success in any study of an HIV cure strategy is going to be very, very difficult.
Paul Sax is Clinical Director of Infectious Diseases at Brigham and Women's Hospital. His blog HIV and ID Observations is part of Journal Watch, where he is Editor-in-Chief of Journal Watch AIDS Clinical Care.
No comments have been made.